wherein:

each **b** is independently 1 or 2;

each $\mathbf{L^b}$ is independently selected from the group consisting of: -O-, -N(H)-, -N(C_{1-3} alkyl)-, -S(O)$_{0-2}$-, -C(=O)-, and C_{1-3} alkylene; and

each $\mathbf{R^{b1}}$ is independently selected from the group consisting of: C_{3-6} cycloalkyl and 4-8 membered heterocyclyl, each of which is optionally substituted with 1-3 $\mathbf{R^g}$;

each $\mathbf{R^c}$ is independently selected from the group consisting of: halo, -CN, -OH, C_{1-6} alkoxy, C_{1-6} haloalkoxy, -N$\mathbf{R^d R^e}$, -C(=O)C_{1-6} alkyl, -C(=O)OC_{1-6} alkyl, -C(=O)N($\mathbf{R^f}$)$_2$, -S(O)$_{0-2}$(C_{1-6} alkyl), and -S(O)$_{0-2}$(C_{1-6} haloalkyl);

each $\mathbf{R^d}$ and $\mathbf{R^e}$ is independently selected from the group consisting of: -H, -C(=O)C_{1-6} alkyl, -C(=O)C_{1-6} haloalkyl, -C(=O)OC_{1-6} alkyl, -C(=O)OC_{1-6} haloalkyl, -C(=O)N($\mathbf{R^f}$)$_2$, -S(O)$_{1-2}$(C_{1-6} alkyl), -S(O)$_{1-2}$(C_{1-6} haloalkyl), -S(O)$_{1-2}$N($\mathbf{R^f}$)$_2$, and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^f}$ is independently selected from the group consisting of: -H and C_{1-6} alkyl optionally substituted with 1-3 $\mathbf{R^h}$;

each $\mathbf{R^g}$ is independently selected from the group consisting of: $\mathbf{R^h}$, oxo, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each $\mathbf{R^h}$ is independently selected from the group consisting of: halo, -CN, -OH, -(C_{0-3} alkylene)-C_{1-6} alkoxy, -(C_{0-3} alkylene)-C_{1-6} haloalkoxy, -(C_{0-3} alkylene)-NH_2, -(C_{0-3} alkylene)-N(H)(C_{1-3} alkyl), and –(C_{0-3} alkylene)-N(C_{1-3} alkyl)$_2$.

In one aspect, the present disclosure refers to a compound of Formula (**I-d1**):



Formula (**I-d1**)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{R^1}$ is -C(O)OH;

$\mathbf{Z^1}$ is CH or N;

$\mathbf{R^2}$ is $-CH_3$ or $-CF_3$;

a1b is 2, 3, or 4;

each $\mathbf{L^{A1b}}$ is $-CH_2-$;

$\mathbf{R^{Ya}}$ is C_{1-3} alkyl optionally substituted with 1-3 -F;

each $\mathbf{R^{Yb}}$ is independently selected from the group consisting of: -F, C_{1-3} alkoxy, and C_{1-3} alkyl optionally substituted with 1-3 -F; and

c1 is 0, 1, or 2.

Also provided herein are pharmaceutical compositions comprising a compound of Formula (**I**) (e.g., Formula (**I-1**) (e.g., Formula (**I-a1**), (**I-a3**), (**I-b1**), (**I-bb1**), (**I-d1**), (**I-dd1**), (**I-e1**), (**I-e1-a**), (**I-f1**), (**I-g1**), (**I-b3**), (**I-c3**), (**I-d3**), or (**I-e3**)), Formula (**I-2**) (e.g., Formula (**I-a2**), (**I-a4**), (**I-b2**), (**I-c2**), (**I-d2**), (**I-e2**), (**I-b4**), (**I-c4**), or (**I-e4**)), Formula (**I-5**) (e.g., (**I-a5**), (**I-b5**), or (**I-e5**)), Formula (**I-6**) (e.g., (**I-a6**), (**I-b6**), or (**I-c6**)), Formula (**II-1**), or Formula (**II-2**)) or Formula (**A**), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In one aspect, the present disclosure refers to a pharmaceutical composition, characterized by comprising a compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

In one aspect, the present disclosure refers to a compound as described herein for use in therapy. In one aspect, the present disclosure refers to use of a compound as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein, in the manufacture of a medicament for treating cancer.

Provided herein are methods for treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a compound of Formula (**I**) (e.g., Formula (**I-1**) (e.g., Formula (**I-a1**), (**I-a3**), (**I-b1**), (**I-bb1**), (**I-d1**), (**I-dd1**), (**I-e1**), (**I-e1-a**), (**I-f1**), (**I-g1**), (**I-b3**), (**I-c3**), (**I-d3**), or (**I-e3**)), Formula (**I-2**) (e.g., Formula (**I-**

a2), (**I-a4**), (**I-b2**), (**I-c2**), (**I-d2**), (**I-e2**), (**I-b4**), (**I-c4**), or (**I-e4**)), Formula (**I-5**) (e.g., (**I-a5**), (**I-b5**), or (**I-e5**)), Formula (**I-6**) (e.g., (**I-a6**), (**I-b6**), or (**I-c6**)), Formula (**II-1**), or Formula (**II-2**)) or Formula (**A**), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein.

Also provided herein is a BCL-X_L protein non-covalently bound with a compound of Formula (**I**) (e.g., Formula (**I-1**) (e.g., Formula (**I-a1**), (**I-a3**), (**I-b1**), (**I-bb1**), (**I-d1**), (**I-dd1**), (**I-e1**), (**I-e1-a**), (**I-f1**), (**I-g1**), (**I-b3**), (**I-c3**), (**I-d3**), or (**I-e3**)), Formula (**I-2**) (e.g., Formula (**I-a2**), (**I-a4**), (**I-b2**), (**I-c2**), (**I-d2**), (**I-e2**), (**I-b4**), (**I-c4**), or (**I-e4**)), Formula (**I-5**) (e.g., (**I-a5**), (**I-b5**), or (**I-e5**)), Formula (**I-6**) (e.g., (**I-a6**), (**I-b6**), or (**I-c6**)), Formula (**II-1**), or Formula (**II-2**)) or Formula (**A**), or a pharmaceutically acceptable salt thereof.

Also provided herein is a ternary complex comprising a BCL-X_L protein, a compound of Formula (**I**) (e.g., Formula (**I-1**) (e.g., Formula (**I-a1**), (**I-a3**), (**I-b1**), (**I-bb1**), (**I-d1**), (**I-dd1**), (**I-e1**), (**I-e1-a**), (**I-f1**), (**I-g1**), (**I-b3**), (**I-c3**), (**I-d3**), or (**I-e3**)), Formula (**I-2**) (e.g., Formula (**I-a2**), (**I-a4**), (**I-b2**), (**I-c2**), (**I-d2**), (**I-e2**), (**I-b4**), (**I-c4**), or (**I-e4**)), Formula (**I-5**) (e.g., (**I-a5**), (**I-b5**), or (**I-e5**)), Formula (**I-6**) (e.g., (**I-a6**), (**I-b6**), or (**I-c6**)), Formula (**II-1**), or Formula (**II-2**)) or Formula (**A**), or a pharmaceutically acceptable salt thereof, and a CRBN protein, or a portion thereof.

To facilitate understanding of the disclosure set forth herein, a number of additional terms are provided. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties. In the case of conflict between the present disclosure and any content incorporated by reference, the present disclosure controls.

The details of one or more examples of the disclosure are set forth in the accompanying drawings and the description below. Other features and advantages of the disclosure will be apparent from the description and drawings, and from the claims.

DETAILED DESCRIPTION

This disclosure provides compounds of Formula (**I**) (e.g., Formula (**I-1**) (e.g., Formula (**I-a1**), (**I-a3**), (**I-b1**), (**I-bb1**), (**I-d1**), (**I-dd1**), (**I-e1**), (**I-e1-a**), (**I-f1**), (**I-g1**), (**I-b3**), (**I-c3**), (**I-